Prognostic Value of Laboratory Biomarkers in Risk Stratification for Short-Term Outcomes in Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis

Key Points

• Prognostic biomarkers enhance the understanding of short-term outcomes in hemophagocytic lymphohistiocytosis.
• Risk stratification based on laboratory biomarkers may lead to better management and treatment.
• Laboratory analysis of biomarkers shows promise for predicting outcomes associated with Epstein-Barr virus.
• Markers identified can help categorize patients based on severity and likely disease progression.